AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23807273
Drug: All DTG
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All DTG treatment groups combined
Trial: 17520463
Drug: Etanercept (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (2 x 50 mg/week)
Trial: 17520463
Drug: Etanercept (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (2 x 25 mg/week)
Trial: 8134674
Drug: Thiopental (4‐6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (4‐6.5 mg/kg)
Trial: 8134674
Drug: Propofol (1.5‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5‐2.5 mg/kg)
Trial: 8134674
Drug: Both induction
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both induction agents
Trial: 27473135
Drug: 0.45 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/d oral conjugated equine estrogens (CEE)
Trial: 27473135
Drug: 50 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg/d transdermal 17β‐estradiol
Trial: 18082886
Drug: Evening-dosed latanoprost/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening-dosed latanoprost/timolol fixed combination
Trial: 11226091
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg IV preoperatively
Trial: 2419019
Drug: inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inosine pranobex (INPX) 3 g/day
Trial: 28552331
Drug: Neurofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback therapy (NFT) for 20 sessions over four weeks
Trial: 25837528
Drug: Methadone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.3 mg/kg)
Trial: 25837528
Drug: Fentanyl (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (12 μg/kg)
Trial: 9766410
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) administration at birth (6 mg/kg elemental magnesium)
Trial: 7816872
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (15 mg males, 10 mg females)
Trial: 7816872
Drug: Rectal suppository
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppository (2.5 mg b.i.d. for 3 days)
Trial: 7816872
Drug: Oral capsule
RxNorm normalized name: Oral Capsule
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule (chronic dosing)
Trial: 7816872
Drug: Inhalation (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation (acute dosing)
Trial: 7816872
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and sublingual routes (acute dosing)
Trial: 7816872
Drug: Fasted and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted and fed states (oral dose)
Trial: 3047526
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day dydrogesterone continuously
Trial: 3047526
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day dydrogesterone for the first 12 days of each month
Trial: 3047526
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated oestrogen continuously
Trial: 28005194
Drug: Dapsone 7.5%
RxNorm normalized name: DAPSONE 7.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 7.5% gel
Trial: 24369764
Drug: Exenatide twice
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice daily (BID)
Trial: 26134916
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily (QD)
Trial: 19706374
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (CR, 4x5 g/day creatine monohydrate for 5 days)
Trial: 19706374
Drug: Placebo (P,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P, same dose of a dextrose‐ascorbic acid placebo)
Trial: 17087116
Drug: Allergen vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen vaccine atomization inhalation (A group)
Trial: 17087116
Drug: Sublingual allergen
RxNorm normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergen vaccine (B group)
Trial: 17087116
Drug: Hypodermic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypodermic injection (C group)
Trial: 11396751
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.5 ml/kg (group B)
Trial: 11396751
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.5 ml/kg with 50 microg/kg midazolam (group BM)
Trial: 2772858
Drug: Allergen inhalation
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen inhalation challenge
Trial: 29121999
Drug: Treatment partner
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment partner and psychoeducation intervention
Trial: 16566675
Drug: COLD-fX (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLD-fX (200 mg/capsule, 2 capsules/day)
Trial: 11571330
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (17.5 mg in the first week, 35.0 mg in the second and third weeks)
Trial: 7923961
Drug: Steroids or
RxNorm normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids or a combination of steroids and cytotoxic therapy
Trial: 3392755
Drug: Reduced Environmental
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Environmental Stimulation Therapy (REST) with anti-alcohol messages for 2.5 hours
Trial: 3392755
Drug: Reduced Environmental
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Environmental Stimulation Therapy (REST) with revised anti-alcohol message for 2.5 hours
Trial: 28095412
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering (target LDL-cholesterol <1.3 mmol/l)
Trial: 28095412
Drug: Guideline lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline lipid lowering (target LDL-c <3.0 mmol/l)
Trial: 28095412
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering therapy
Trial: 28095412
Drug: Guideline lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline lipid lowering therapy
Trial: 21492255
Drug: 1.5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg/day of liposomal amphotericin B for 5 days
Trial: 17573730
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized cat dander extract
Trial: 15367188
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no Emdogain application)
Trial: 7628832
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 IU insulin/kg body weight) to induce hypoglycemia
Trial: 2699072
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy (60 Gy) and salvage cystectomy
Trial: 21304241
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg (half-dose)
Trial: 21304241
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (standard-dose)
Trial: 15028562
Drug: Montelukast plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast plus Fluticasone propionate (10 mg + 440 microg/day)
Trial: 9272100
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (2 IU/m2)
Trial: 6815696
Drug: 6-azamianserin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-azamianserin (2 mg)
Trial: 6815696
Drug: mianserin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (6 mg)
Trial: 6815696
Drug: flurazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flurazepam (10 mg)
Trial: 6815696
Drug: 6-azamianserin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-azamianserin (0.5 and 1.0 mg of (+) and (‐) enantiomers)
Trial: 31919289
Drug: NICU music
RxNorm normalized name: Nicumalon
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NICU music therapy intervention, Multimodal Neurologic Enhancement
Trial: 30489382
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of oral ropinirole twice daily added on to current medication
Trial: 30489382
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily added on to current medication
Trial: 18757262
Drug: Fulvestrant loading
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant loading dose regimen (500 mg on day 0, 250 mg on days 14 and 28, then 250 mg each month thereafter)
Trial: 18757262
Drug: Fulvestrant loading
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant loading dose regimen
Trial: 9187987
Drug: Cardiopulmonary bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiopulmonary bypass (CPB) flow rate of 2.3 L/min/m2
Trial: 9187987
Drug: Cardiopulmonary bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiopulmonary bypass (CPB) flow rate of 1.2 L/min/m2
Trial: 3890463
Drug: Daily whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily whole body soap wash and umbilical cleansing with 4% chlorhexidine detergent solution (Hibiscrub)
Trial: 3890463
Drug: Daily whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily whole body soap wash and umbilical cleansing with benzine solution
Trial: 3890463
Drug: Daily whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily whole body soap wash and umbilical cleansing with 0.05% chlorhexidine
Trial: 3890463
Drug: Daily whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily whole body soap wash (control group)
Trial: 26951414
Drug: Mindfulness‐Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐Based Therapy for Insomnia (MBTI)
Trial: 17305624
Drug: Electrostimulation using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulation using a device mounted on an individualized intra‐oral removable appliance for 10 minutes.
Trial: 15117900
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist leuprolide acetate followed by recombinant human FSH (r-hFSH; 100 IU/day) and hCG (2000 IU/twice a week) for 2 months (Group A1 and B1)
Trial: 7506160
Drug: nimesulide (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (200mg 3 times daily)
Trial: 7506160
Drug: diclofenac (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac (100mg 3 times daily)
Trial: 3552694
Drug: Single-dose fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose fosfomycin trometamol (3 g)
Trial: 3552694
Drug: Pipemidic acid
RxNorm normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipemidic acid (200-gram doses b.i.d. for 7 days)
Trial: 23558093
Drug: Deleobuvir 400
RxNorm normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deleobuvir 400 mg three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks
Trial: 23558093
Drug: Deleobuvir 600
RxNorm normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deleobuvir 600 mg three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks
Trial: 21234767
Drug: 0.125 mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg/kg/min landiolol
Trial: 21234767
Drug: 0.25 mg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/min landiolol
Trial: 18445733
Drug: Teaching a
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching a new word (e.g. 'whisk') paired with a novel picture, repeated exposure not specified.
Trial: 8232927
Drug: Sensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensory stimulation (acupuncture) twice a week for 10 weeks
Trial: 8232927
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving daily physiotherapy and occupational therapy
Trial: 30624092
Drug: OFD +
RxNorm normalized name: OFDZ
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFD + L-PRF
Trial: 26242112
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy combined with Chinese medicine (CM)
Trial: 16890064
Drug: Morphine Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine Ondansetron PCA
Trial: 14693593
Drug: 2-chloroprocaine with
RxNorm normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-chloroprocaine with fentanyl (20 micro g)
Trial: 11527621
Drug: Mild renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild renal insufficiency (creatinine 1.2 mg/dl to 1.4 mg/dl)
Trial: 11527621
Drug: Moderate renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate renal insufficiency (creatinine >1.4 mg/dl)
Trial: 11527621
Drug: Normal renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal renal function (creatinine < 1.2 mg/dl)
Trial: 9000046
Drug: Nonpharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatment for CFS
Trial: 3727591
Drug: 13% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13% maltodextrin solution (52 kcal, 160 mOsm/l)
Trial: 19025038
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no special treatment
Trial: 12521598
Drug: Topical alpha-tocotrienol
RxNorm normalized name: .ALPHA.-TOCOTRIENOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alpha-tocotrienol (5% w/vol)
Trial: 8713558
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg alfuzosin
Trial: 8713558
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alfuzosin
Trial: 8713558
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg alfuzosin
Trial: 1854053
Drug: Additional dose
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional dose of propofol (0.7 mg.kg‐1) in group P2
Trial: 1854053
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of propofol (1.5 mg.kg‐1) in group P1
Trial: 25180056
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg twice per day
Trial: 25180056
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg twice per day
Trial: 25180056
Drug: Melatonin 8
RxNorm normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 8 mg twice per day
Trial: 21965229
Drug: Nonstandardised antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstandardised antibiotic therapy (control)
Trial: 21965229
Drug: β-lactam plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam plus macrolide combination (BLM)
Trial: 17094530
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (1 mg/kg)
Trial: 11321236
Drug: GM-CSF (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (80 microg or 250 microg) administered as a single injection with the first and second doses of hepatitis B vaccine
Trial: 11321236
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered at 0, 1, and 6 months
Trial: 3137632
Drug: 5-methoxypsoralen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-methoxypsoralen (40 mg daily at 9 p.m.)
Trial: 31820602
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at 'three points of iliolumbar' combined with celecoxib (200 mg once a day for 3 days)
Trial: 31820602
Drug: Celecoxib alone
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib alone (200 mg once a day for 3 days)
Trial: 20702523
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 12 months
Trial: 23436915
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment for 24 months
Trial: 18959591
Drug: Hydro-alcoholic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydro-alcoholic solution of a phytocompound (20 gtt 30 min before meals for 2 weeks)
Trial: 12043864
Drug: ProFile Ni‐Ti.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProFile Ni‐Ti.06 taper Series 29
Trial: 9821653
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules in humans
Trial: 9821653
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated tablets in humans
Trial: 9821653
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules in dogs (pentagastrin pretreated)
Trial: 9821653
Drug: Conventional capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional capsules in dogs (saline pretreated)
Trial: 7666816
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol patch (50 micrograms daily) + levonorgestrel-releasing IUD (20 micrograms daily)
Trial: 7666816
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (2 mg of estradiol + 1 mg of noretisterone acetate daily)
Trial: 2757882
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release acetazolamide (SRA) 500 mg once or twice daily
Trial: 2757882
Drug: Conventional acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional acetazolamide (CA) 500 mg once or twice daily
Trial: 772394
Drug: Mesterolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesterolone (2 mg/kg orally for 6 months)
Trial: 24661263
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Cognitive-Behavioral Therapy (CBT)
Trial: 21753776
Drug: Lactotripeptides (LTPs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactotripeptides (LTPs) at 3 mg per day for 6 weeks
Trial: 19005687
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g ginger daily